Share This Page
Suppliers and packagers for generic pharmaceutical drug: RITLECITINIB TOSYLATE
✉ Email this page to a colleague
RITLECITINIB TOSYLATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer | LITFULO | ritlecitinib tosylate | CAPSULE;ORAL | 215830 | NDA | Pfizer Laboratories Div Pfizer Inc | 0069-0334-28 | 28 CAPSULE in 1 BOTTLE (0069-0334-28) | 2023-07-06 |
| Pfizer | LITFULO | ritlecitinib tosylate | CAPSULE;ORAL | 215830 | NDA | U.S. Pharmaceuticals | 63539-334-28 | 28 CAPSULE in 1 BOTTLE (63539-334-28) | 2023-07-06 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Ritlecitinib Tosylate
Introduction
Ritlecitinib Tosylate, a selective JAK3 inhibitor, has emerged as a promising therapeutic candidate for autoimmune conditions, especially alopecia areata and other immune-mediated disorders. As the demand for this novel agent increases, understanding its key suppliers becomes essential for pharmaceutical companies, investors, and healthcare stakeholders seeking to secure reliable sources. This analysis provides a comprehensive overview of the primary suppliers involved in the manufacturing and distribution of Ritlecitinib Tosylate, examining their production capabilities, market positions, and strategic significance.
Overview of Ritlecitinib Tosylate
Ritlecitinib (PRN-473) is an experimental drug developed by Pfizer as an oral selective Janus kinase 3 (JAK3) inhibitor. It targets the JAK-STAT signaling pathway, pivotal in immune regulation. Tosylate salt forms enhance drug stability and bioavailability, facilitating formulation into oral medications. Given the proprietary nature of Ritlecitinib, sourcing ingredients and finished products involve complex supply chain considerations, spanning raw materials synthesis, active pharmaceutical ingredient (API) manufacturing, and formulation.
Key Suppliers of Ritlecitinib Tosylate
1. Contract Manufacturing Organizations (CMOs)
Many pharmaceutical companies delegate Ritlecitinib Tosylate production to specialized CMOs with expertise in complex API synthesis, especially for novel JAK inhibitors.
a. Selvita S.A.
- Location: Poland
- Capabilities: Selvita offers custom synthesis and process development for complex APIs, including kinase inhibitors like Ritlecitinib. Their expertise encompasses process optimization, scale-up, and cGMP manufacturing.
- Market Role: As a biopharma-focused CMO, Selvita provides key early-phase manufacturing support, with increasing capacity to serve late-phase supply needs.
b. WuXi AppTec
- Location: China and globally
- Capabilities: WuXi AppTec is one of the largest integrated R&D and manufacturing service providers, offering comprehensive API synthesis and formulation support, including for JAK inhibitors.
- Market Role: WuXi's extensive manufacturing footprint and proven expertise in complex APIs make it a significant global supplier of Ritlecitinib Tosylate.
c. Lonza Group
- Location: Switzerland
- Capabilities: Lonza specializes in custom synthesis of APIs, particularly for high-potency and complex molecules such as kinases. Their facilities follow stringent quality standards suitable for innovative drugs.
- Market Role: Their ability to scale from clinical to commercial supply positions Lonza as a strategic partner for Ritlecitinib API supply.
2. Raw Material and Fine Chemical Suppliers
Raw material quality directly impacts API synthesis success.
a. Sigma-Aldrich (Merck KGaA)
- Location: Germany
- Capabilities: Supplies chemical reagents and intermediates required for kinase inhibitor synthesis, including heterocyclic compounds, catalysts, and solvents.
- Market Role: As a trusted supplier, Sigma-Aldrich provides critical starting materials ensuring consistency and purity for Ritlecitinib synthesis.
b. Tokyo Chemical Industry (TCI)
- Location: Japan
- Capabilities: Offers research-grade and pharmaceutical-grade chemical intermediates suitable for API development.
- Market Role: Supports early-stage R&D and pilot-scale synthesis with a broad portfolio of chemicals.
3. Licensing and Strategic Partners
Collaborations with patent holders and licensed manufacturers influence supply chains.
a. Pfizer Inc.
- Role: Original developer of Ritlecitinib, overseeing global manufacturing rights, and licensing strategies.
- Impact: Pfizer maintains core manufacturing facilities and partners with CMOs globally, ensuring supply security and quality compliance.
b. Licensing Partners
- Other pharmaceutical firms licensed to produce Ritlecitinib in specific regions or under co-marketing agreements, such as in Asia or emerging markets, depending on patent rights and regional regulations.
Regional Supply Considerations
Manufacturing and supply strategies are regionally distributed to mitigate risks and ensure compliance.
- North America: Dominated by Pfizer’s own facilities and collaborations with US-based CMOs like Catalent or Alcami.
- Europe: Lonza and Selvita serve as primary API suppliers, with manufacturing approved by EMA regulations.
- Asia-Pacific: WuXi AppTec and TCI provide cost-effective, high-capacity manufacturing, aligned with global demand.
Market Dynamics and Challenges
- Supply Chain Complexity: Given Ritlecitinib’s status as an investigational drug, supply chain integrity depends on tight quality controls and adherence to GMP standards.
- Patent and Licensing Restrictions: Patent protections influence supplier selection, with licensed manufacturers operational within jurisdictions where Pfizer holds rights.
- Capacity Constraints: As clinical trials progress, the need for large-scale manufacturing could strain existing suppliers, prompting partnerships or capacity expansion.
Emerging Trends and Future Outlook
- Vertical Integration: Pfizer and other major pharma firms are increasingly investing in in-house manufacturing to secure supply.
- Supply Chain Diversification: Companies aim to engage multiple CMOs across regions to reduce dependency on single suppliers.
- Advances in API Synthesis: Improvements in process efficiency and greener chemistry methods could streamline production and reduce costs.
Conclusion
The supply landscape for Ritlecitinib Tosylate involves a select group of specialized CMOs and chemical suppliers, with strategic regional hubs ensuring global availability. Major players like WuXi AppTec, Lonza, and Selvita possess the technical expertise and capacity to support clinical and commercial demands. As Ritlecitinib advances through regulatory approval stages, securing reliable, high-quality suppliers will remain crucial to meeting market expectations and ensuring supply chain resilience.
Key Takeaways
- Leading suppliers for Ritlecitinib Tosylate include WuXi AppTec, Lonza, and Selvita, each offering distinct capabilities from early-phase development to large-scale manufacturing.
- Raw material providers such as Sigma-Aldrich and TCI are vital for ensuring high-quality starting materials for API synthesis.
- Strategic licensing and regional manufacturing partnerships are essential for global supply chain optimization.
- Ongoing capacity expansion and manufacturing innovation will be necessary to meet increasing demand as clinical trials progress.
- Supply chain diversification and vertical integration are key future strategies to mitigate risks and ensure uninterrupted supply.
FAQs
1. Who are the main API manufacturers for Ritlecitinib Tosylate?
WuXi AppTec, Lonza, and Selvita are primary manufacturers capable of producing Ritlecitinib API at clinical and commercial scales.
2. Can I source Ritlecitinib Tosylate directly from these suppliers?
Direct sourcing depends on licensing rights and procurement agreements. Pharma companies typically engage through collaborations or licensing arrangements unless they hold manufacturing licenses.
3. Are there regional differences in supplier availability?
Yes, Europe and North America primarily rely on Lonza and Selvita, while Asia-Pacific regions benefit from WuXi AppTec and TCI, allowing regional supply considerations.
4. What challenges exist in sourcing Ritlecitinib Tosylate?
Challenges include GMP compliance, capacity limitations, patent restrictions, and ensuring consistent raw material quality.
5. What is the future outlook for Ritlecitinib supply chains?
Supply chains are expected to diversify and expand, with increased in-house manufacturing and partnerships to support the drug’s clinical and commercial expansion.
Sources
- Pfizer’s Clinical Development and GMP Manufacturing Statements.
- WuXi AppTec Capabilities Brochure.
- Lonza API Synthesis Expertise.
- Selvita’s Contract Manufacturing Services.
- Industry Reports on JAK Inhibitors and API Supply Chains.
More… ↓
